|
Apr 29
|
Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States
|
|
Apr 29
|
Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
|
|
Apr 27
|
Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks
|
|
Apr 26
|
Gilead Sciences First Quarter 2025 Earnings: Misses Expectations
|
|
Apr 25
|
Why Gilead Sciences Stock Slipped Today
|
|
Apr 25
|
Gilead Dives As Its Biggest Moneymaker Misses. Here's Why It Could Still Be A 'Safe Haven' Stock.
|
|
Apr 25
|
Gilead Delivers Lackluster Q1 Revenue on Trodelvy Miss, Oppenheimer Says
|
|
Apr 25
|
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline
|
|
Apr 25
|
Gilead Sciences Stock Falls as Slumping COVID-19, Cancer Drug Sales Hit Revenue
|
|
Apr 25
|
Gilead Sciences Earnings Were Solid. Why the Stock Is Dropping.
|
|
Apr 25
|
Q1 2025 Gilead Sciences Inc Earnings Call
|
|
Apr 25
|
Gilead leans on HIV drugs as oncology sales slow
|
|
Apr 25
|
3 High Growth Tech Stocks Leading The US Market
|
|
Apr 24
|
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say
|
|
Apr 24
|
Gilead Sciences posts mixed Q1 results
|
|
Apr 24
|
Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates
|
|
Apr 11
|
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs
|
|
Apr 10
|
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
|
|
Apr 10
|
PatientView Ranks Gilead "Best" at ESG
|
|
Apr 9
|
Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know
|